completed enrollment - The FDA granted Breakthrough Therapy Designation to oral infigratinib for achondroplasia - Regenerative Medicine Advanced Therapy Designation awarded to BBP-812 for Canavan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback